A closer look at the recommended criteria for disclosing genetic results: Perspectives of medical genetic specialists, genomic researchers, and institutional review board chairs

Debra S. Brandt, Laura Shinkunas, Stephen L. Hillis, Sandra E. Daack-Hirsch, Martha Driessnack, Nancy R. Downing, Megan F. Liu, Lisa L. Shah, Janet K. Williams, Christian M. Simon

研究成果: 雜誌貢獻文章

23 引文 斯高帕斯(Scopus)

摘要

Next generation sequencing offers benefit of improved health through knowledge, but comes with challenges, such as inevitable incidental findings (IFs). The applicability of recommended criteria for disclosure of individual results when applied to disclosure of IFs is not well known. The purpose of this study was to examine how medical genetic specialists, genomic researchers, and Institutional Review Board (IRB) chairs perceive the importance of recommended criteria when applied to genetic/genomic IFs. We conducted telephone interviews with medical genetic specialists (genetic counselors, genetic nurses, medical geneticists, laboratory professionals), genomic researchers, and IRB chairs (N = 103). Respondents rated and discussed the importance of nine recommended criteria regarding disclosure of genetic/genomic IFs. Stakeholders agreed the most important criteria for disclosure were: (1) the IF points to a life-threatening condition; (2) there is a treatment; (3) individuals indicate in writing they wanted to be informed of IFs. Criteria rated less important were: analytic validity, high penetrance, association with a young age of onset and relative risk more than 2.0. Respondents indicated that some technical criteria were confusing, and in need of context. Our findings suggest that development of guidelines regarding management of IF include multiple stakeholders' perspectives and be based on a common language.

原文英語
頁(從 - 到)544-553
頁數10
期刊Journal of Genetic Counseling
22
發行號4
DOIs
出版狀態已發佈 - 八月 2013

    指紋

ASJC Scopus subject areas

  • Genetics(clinical)
  • Medicine(all)

引用此